uniQure N.V. (QURE)
- Previous Close
4.7500 - Open
4.7700 - Bid 4.5800 x 100
- Ask 4.5900 x 100
- Day's Range
4.5750 - 4.7800 - 52 Week Range
4.5750 - 22.4800 - Volume
278,456 - Avg. Volume
969,440 - Market Cap (intraday)
219.339M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-6.4700 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.85
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
www.uniqure.comRecent News: QURE
Performance Overview: QURE
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QURE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QURE
Valuation Measures
Market Cap
227.23M
Enterprise Value
-252.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.29
Price/Book (mrq)
1.09
Enterprise Value/Revenue
-15.92
Enterprise Value/EBITDA
1.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.72%
Return on Equity (ttm)
-90.24%
Revenue (ttm)
15.84M
Net Income Avi to Common (ttm)
-308.48M
Diluted EPS (ttm)
-6.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
617.89M
Total Debt/Equity (mrq)
256.49%
Levered Free Cash Flow (ttm)
-65.23M
Research Analysis: QURE
Company Insights: QURE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: QURE
QURE: Lowering target price to $8.00
UNIQURE NV has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetQURE: What does Argus have to say about QURE?
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetQURE: What does Argus have to say about QURE?
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetQURE: Lowering target price to $9.00
UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target